BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 15647250)

  • 1. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain.
    Haché G; Liddament MT; Harris RS
    J Biol Chem; 2005 Mar; 280(12):10920-4. PubMed ID: 15647250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
    Langlois MA; Beale RC; Conticello SG; Neuberger MS
    Nucleic Acids Res; 2005; 33(6):1913-23. PubMed ID: 15809227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
    Liddament MT; Brown WL; Schumacher AJ; Harris RS
    Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
    Holmes RK; Koning FA; Bishop KN; Malim MH
    J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.
    Wang X; Dolan PT; Dang Y; Zheng YH
    J Biol Chem; 2007 Jan; 282(3):1585-94. PubMed ID: 17142455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins.
    Jónsson SR; Haché G; Stenglein MD; Fahrenkrug SC; Andrésdóttir V; Harris RS
    Nucleic Acids Res; 2006; 34(19):5683-94. PubMed ID: 17038330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.
    Lei YC; Tian YJ; Ding HH; Wang BJ; Yang Y; Hao YH; Zhao XP; Lu MJ; Gong FL; Yang DL
    World J Gastroenterol; 2006 Dec; 12(46):7488-96. PubMed ID: 17167839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo.
    Beale RC; Petersen-Mahrt SK; Watt IN; Harris RS; Rada C; Neuberger MS
    J Mol Biol; 2004 Mar; 337(3):585-96. PubMed ID: 15019779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.
    Zennou V; Bieniasz PD
    Virology; 2006 May; 349(1):31-40. PubMed ID: 16460778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F.
    Nagao T; Yamashita T; Miyake A; Uchiyama T; Nomaguchi M; Adachi A
    J Med Invest; 2010 Feb; 57(1-2):89-94. PubMed ID: 20299747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOBEC-mediated interference with hepadnavirus production.
    Rösler C; Köck J; Kann M; Malim MH; Blum HE; Baumert TF; von Weizsäcker F
    Hepatology; 2005 Aug; 42(2):301-9. PubMed ID: 16025511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
    Bishop KN; Holmes RK; Malim MH
    J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complementary function of the two catalytic domains of APOBEC3G.
    Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
    Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast.
    Schumacher AJ; Nissley DV; Harris RS
    Proc Natl Acad Sci U S A; 2005 Jul; 102(28):9854-9. PubMed ID: 16000409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.
    Wichroski MJ; Robb GB; Rana TM
    PLoS Pathog; 2006 May; 2(5):e41. PubMed ID: 16699599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase.
    Kohli RM; Abrams SR; Gajula KS; Maul RW; Gearhart PJ; Stivers JT
    J Biol Chem; 2009 Aug; 284(34):22898-904. PubMed ID: 19561087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution.
    Rathore A; Carpenter MA; Demir Ö; Ikeda T; Li M; Shaban NM; Law EK; Anokhin D; Brown WL; Amaro RE; Harris RS
    J Mol Biol; 2013 Nov; 425(22):4442-54. PubMed ID: 23938202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guanine-adenine bias: a general property of retroid viruses that is unrelated to host-induced hypermutation.
    Müller V; Bonhoeffer S
    Trends Genet; 2005 May; 21(5):264-8. PubMed ID: 15851060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.